PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1809348
Case Report with Review of Literature

Gelatinous Marrow Transformation in Chronic Myeloid Leukemia Post-Dasatinib Treatment: A Case Report with Review of Literature

Gayathri Kini 
1   Department of Pathology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India
,
Chandni Bhandary
2   Department of Pathology, Father Muller Medical College, Mangalore, Karnataka, India
,
Poornachandra Vivekananda
1   Department of Pathology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India
,
Chandrashekhar S. Jayaprakash
2   Department of Pathology, Father Muller Medical College, Mangalore, Karnataka, India
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Gelatinous marrow transformation (GMT) is characterized by accumulation of extracellular gelatinous substances such as mucopolysaccharides, fat cell atrophy, and focal loss of hematopoietic cells. It is a rare disorder of unknown pathogenesis. Anorexia nervosa, acute febrile state, acquired immunodeficiency syndrome, heart failure, lymphomas, and carcinomas are some of the entities associated with GMT. A 57-year-old male patient presented with abdominal distension of 1-month duration. He was diagnosed as chronic myeloid leukemia (CML) and treated with imatinib. Repeat testing 2 years later revealed a normal hemogram. However, in view of his BCR::ABL1 levels of 17%, he was switched to dasatinib. Patient presented with fever, fatigue, and reduced appetite 4 months later. Hemogram revealed pancytopenia. Bone marrow examination showed a hypocellular marrow with trilineage suppression and gelatinous transformation. GMT in CML patients' posttherapy is a rare encounter. It is essential to identify this clinical scenario for optimal patient management and monitoring progression of disease.

Keywords

dasatinib - gelatinous marrow transformation - chronic myeloid leukemia - case report

Note

The manuscript has been read and approved by all the authors, that the requirements for authorship have been met, and we all believe that the manuscript represents honest work.


Authors' Contributions

Concept: C.B.P.

Literature search: G.K., P.V.

Data acquisition: G.K., C.B.P.

Manuscript preparation: G.K., P.V.

Manuscript editing: C.B.P.

Manuscript review: C.B.P., J.C.S.


Patient's Consent

The institutional ethics committee exempted the study from review and issued a waiver for patient written consent in view of patient identifiers/photographs not being used (Ref No: FMIEC/CCM/803/2022).




Publikationsverlauf

Artikel online veröffentlicht:
04. Juni 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Böhm J. Gelatinous transformation of the bone marrow: the spectrum of underlying diseases. Am J Surg Pathol 2000; 24 (01) 56-65
    PubMedSuche in Google Scholar
  • 2 Sharma SK, Choudhary D, Handoo A. et al. Gelatinous transformation of bone marrow following the use of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Res Rep 2013; 2 (01) 7-8
    PubMedSuche in Google Scholar
  • 3 Shergill KK, Shergill GS, Pillai HJ. Gelatinous transformation of bone marrow: rare or underdiagnosed?. Autops Case Rep 2017; 7 (04) 8-17
    CrossrefPubMedSuche in Google Scholar
  • 4 Ram R, Gafter-Gvili A, Okon E, Pazgal I, Shpilberg O, Raanani P. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?. Acta Haematol 2008; 119 (02) 104-107
    PubMedSuche in Google Scholar
  • 5 Singh S, Gupta M, Singh G. et al. Gelatinous transformation of bone marrow: a prospective tertiary center study, indicating varying trends in epidemiology and pathogenesis. Indian J Hematol Blood Transfus 2016; 32 (Suppl. 01) 358-360
    PubMedSuche in Google Scholar
  • 6 Hermel DJ, Nael A, Lu YT. et al. Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib. Anticancer Drugs 2019; 30 (04) 416-421
    PubMedSuche in Google Scholar
  • 7 Hong FS, Mitchell CA, Zantomio D. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia. Pathology 2010; 42 (01) 84-85
    PubMedSuche in Google Scholar
  • 8 Chang E, Rivero G, Jiang B, Yellapragada S, Thiagarajan P. Gelatinous marrow transformation associated with imatinib: case report and literature review. Case Rep Hematol 2017; 2017: 1950724
    PubMedSuche in Google Scholar
  • 9 Paul TR, Uppin SG, Uppin MS, Jacob RT, Rao DR, Rajappa SJ. Evaluation of cytopenias occurring in imatinib treated chronic myeloid leukemia (CML) patients. Indian J Hematol Blood Transfus 2010; 26 (02) 56-61
    PubMedSuche in Google Scholar